EFFICACY OUTCOMES IN PATIENTS WITH KNEE OSTEOARTHRITIS: PER-PROTOCOL ANALYSES FROM SPRINGBOARD, A PHASE 2, RANDOMIZED, 24-WEEK STUDY OF EP-104IAR (LONG-ACTING INTRA-ARTICULAR INJECTION OF FLUTICASONE PROPIONATE)

Purpose (the aim of the study): Global prevalence of knee osteoarthritis (KOA) was estimated at 365 million in 2019. Recommended treatment includes topical and oral NSAIDs, and intra-articular (IA) corticosteroids. However, available IA corticosteroids have limited duration of effect and risk of side effects. EP-104IAR is a long-acting fluticasone propionate (FP) IA injection being developed for OA symptoms. EP-104IAR employs a novel controlled-release technology to optimize the pharmacokinetics of FP, maximizing IA residence time while limiting systemic exposure, providing a greater duration of efficacy with fewer systemic and local side effects.